The most common side effects were grade 1 or 2, including injection‐site pain, fever, vomiting, and headache, indicating that CIMAvax‐EGF has an acceptable safety profile.[425] These findings suggest that targeting EGF through vaccination can effectively inhibit EGFR‐driven tumor growth and improve survival outcomes in patients with advanced NSCLC. Here, EGF is linked to non-small cell lung carcinoma.